Yet he wrote this in today's Barron's:
A SECTOR THAT WE'VE LONG liked but haven't featured with any frequency of late in this sacred space are the drug makers. It's no secret that many of the big pharma companies have had the sad experience of seeing their bestsellers come off patent and, in a flash, found themselves in a no-holds-barred price war with generic producers. Pfizer (ticker: PFE) and its lockbuster Lipitor leap to mind.
If not exactly a sleeping giant, Pfizer has induced its share of snores among analysts, where opinion is split between the yawners who suggest it be sold and the tepid enthusiasts who kind of like it. We're attracted to the company precisely because nobody seems to be pounding the table for the stock, which has been rather a listless performer.
As chance would have it, a favorable report on Pfizer from First Global crossed our desk last week. Kavita Thomas, who wrote the analysis, is to be commended for being upfront about the company's problems rather than simply rah-rah about its prospects. She's quick to point out that revenue fell in the fourth quarter, but it was better than she anticipated.
Kavita also reports the Pfizer's pipeline is stuffed with promise. Just by way of illustration, the key data on its Alzheimer's drug bapineuzamab (try saying that aloud while chewing on a pretzel) will be revealed this year, its pneumococcal vaccine is slated to be released next month, and its kidney-cancer pill won recent approval.
Sometime this year, too, the company will decide whether to sell or spin off its animal-health and nutrition businesses, both of which, she notes, enjoyed double-digit growth last year. Whatever their disposition, Pfizer is in line for a handsome return.
Her forecast is for earnings of $2.27 a share this year and $2.34 next. Last we looked the stock was 21, so it's selling at only nine times estimated 2013 earnings, the lowest P/E among the majors, boasts strong operating cash flow and its shares yield more than 4%. Best of all, as we indicated, it's pretty much unloved.
Comments? E-mail us at email@example.com
Why should Hotpanera or anyone else continue educating & informing you, dirt bag?
Everyone knows you're wrong. Repeating the same ignorant, idiotic lunacies over & over only makes you more of a loser.
BTW, when are you going to behave like a human & accept Hotpanera's offer to prove he's a lawyer?
Once again it's "say something stupid, get caught, obfuscate".
It was YOU who said unequivocally that Pfe shareholders might only get 90 shares of Pfe after a spin-off of Animal Health. That was absolutely wrong. Your Bmy non-analogy only made it worse. Yet, you refuse to correct the mistake which could easily have misled people had I and Pebble not corrected it.
How can you possibly think that you are helping your image by such blatantly untruthful conduct day after day, and why would that be important to you when you supposedly don't respect anybody here? Just asking.
being a guy should have surmised you would not understand---lolol---she said you TWO are ONE of a kind--in other words unique individuals---not similar--- FOR SURE--but when they make you two the throw away the mold---maybe now you gets it... nuther misunderstanding in cyberspace---full of em----aint seen that avy guy lately
--i am but nippy is on a mission---lololo and you two are one of a kind and not going away---lolol
well being a woman I wouldn't expect you to understand...lololol...we're not two of a kind, we're polar opposites..lololol
ot is ot----it is so nonsense does not have to be read by serious readers---if there are any---your best response would be none and to just ignore my posts---we is just playing anyway--i am but nippy is on a mission---lololo and you two are one of a kind and not going away---lolol